Summary: NICE backs AUCATZYL for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL, the CAR-T cell therapy obatabtagene autoleucel (also known as obecabtagene autoleucel), for use within the UK’s healthcare system. The decision marks a significant milestone for patients with certain hematologic cancers and highlights the growing role of…